WO2014070979A1 - Inhibitors of cytomegalovirus - Google Patents

Inhibitors of cytomegalovirus Download PDF

Info

Publication number
WO2014070979A1
WO2014070979A1 PCT/US2013/067674 US2013067674W WO2014070979A1 WO 2014070979 A1 WO2014070979 A1 WO 2014070979A1 US 2013067674 W US2013067674 W US 2013067674W WO 2014070979 A1 WO2014070979 A1 WO 2014070979A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
mmol
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US2013/067674
Other languages
English (en)
French (fr)
Inventor
Lee Fader
Mathieu Parisien
Carl Thibeault
Louis Morency
Martin Duplessis
Clint James
Sebastien Morin
James Gillard
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Priority to EP13792795.0A priority Critical patent/EP2914592B1/en
Priority to US14/440,087 priority patent/US9334249B2/en
Priority to JP2015540765A priority patent/JP6372666B2/ja
Publication of WO2014070979A1 publication Critical patent/WO2014070979A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to diamido arene analogs and their use as inhibitors of cytomegalovirus (CMV) replication, pharmaceutical compositions containing such analogs, and methods of using these analogs in the treatment and prevention of CMV disease and/or infection.
  • CMV cytomegalovirus
  • CMV a ⁇ -herpes virus
  • CMV replication in the immunosuppressed host if left unchecked, results in severe morbidity, mortality and other complications such as predisposition to bacterial and fungal infections, graft versus host disease and potential graft failure.
  • CMV infection is the most common infection in patients undergoing hematopoietic stem cell transplantation (HCT) or solid organ transplantation (SOT).
  • HCT hematopoietic stem cell transplantation
  • SOT solid organ transplantation
  • CMV is prevalent in 50-80% adult transplant candidates and found at lower prevalence in children.
  • the current Gold Standard (Valganciclovir, Ganciclovir) is myelotoxic, and interferes with bone marrow engraftment in HCT.
  • the present invention provides a novel series of compounds having inhibitory activity against CMV replication. Further objects of this invention arise for the one skilled in the art from the following description and the examples.
  • An embodiment of the invention provides a compound of Formula (I) or racemate, enantiomer, diastereomer or tautomer thereof:
  • Ring Z is selected from the group consisting of phenyl, pyridine, pyridinone, benzimidazole and benzothiazole wherein each said phenyl, pyridine, pyridinone, benzimidazole and benzothiazole are optionally mono-, di- or tri- substituted with Z 1 ;
  • Z 1 is each independently selected from the group consisting of (d ⁇ alkyl, -(C -6 )alkyl- (C 3 - 7 )cycloalkyL -(Ci- 6 )alkyl-heteroaryl, -(Ci- 6 )alkyl-heterocyclyl and -0-(Ci- 6 )alkyl;
  • R 2 is K or K ;
  • R 2A is H or (d_ 6 )alkyl
  • R 3 is absent, (C 3 . 7 )cycloalkyl or (C -6 )alkyl optionally mono-, di- or tri-substituted with R 3A ;
  • R 4 is halo, (C 1-6 )haloalkyl, -CN, OH, -0-(C 1-6 )alkyl or (C 1-6 )alkyl,
  • R 2 , R 4 and n are as defined above and Z 4 is S or N(H).
  • R 2 , R 4 and n are as defined above.
  • R 2 , R 4 and n are as defined above.
  • Another embodiment of the invention provides a compound having the formula: wherein R 2 , R 4 and n are as defined above and one of Z 2 and Z 3 is N and the other of Z 2 and Z 3 is CH.
  • R 2 , R 4 and n are as defined above.
  • Another embodiment of this invention provides a compound of Formula (I), or a
  • composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition according to this invention further comprises a therapeutically effective amount of at least one other antiviral agent.
  • the invention also provides the use of a pharmaceutical composition as described hereinabove for the treatment of a CMV infection in a human being having or at risk of having the infection.
  • the invention also provides the use of a pharmaceutical composition as described hereinabove for the treatment of CMV disease in a human being having or at risk of having the disease.
  • Another aspect of the invention involves a method of treating or preventing CMV disease and/or infection in a human being by administering to the human being an anti-CMV virally effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a composition as described above, alone or in combination with at least one other antiviral agent, administered together or separately.
  • An additional aspect of this invention refers to an article of manufacture comprising a composition effective to treat CMV disease and/or infection; and packaging material comprising a label which indicates that the composition can be used to treat disease and/or infection by CMV; wherein the composition comprises a compound of formula (I) according to this invention or a pharmaceutically acceptable salt thereof.
  • Still another aspect of this invention relates to a method of inhibiting the replication of CMV comprising exposing the virus to an effective amount of the compound of formula (I), or a salt thereof, under conditions where replication of CMV is inhibited.
  • Ci_ 6 -alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
  • the first named subgroup is the radical attachment point, for example, the substituent "-Ci_ 3 -alkyl-aryl” means an aryl group which is bound to a Ci- 3 -alkyl-group, with the C! -3-alkyl group bound to the core. Unless specifically stated otherwise, for groups comprising two or more subgroups, the substituent may be attached to either subgroup.
  • a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers, atropisomers) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of
  • enantiomers of the compounds of the present invention Preparation of pure stereoisomers, e.g. enantiomers and diastereomers, or mixtures of desired enantiomeric excess (ee) or
  • enantiomeric purity are accomplished by one or more of the many methods of (a) separation or resolution of enantiomers, or (b) enantioselective synthesis known to those of skill in the art, or a combination thereof.
  • These resolution methods generally rely on chiral recognition and include but not limited to chromatography using chiral stationary phases, enantioselective host-guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and nonenzymatic kinetic resolution, or spontaneous enantioselective crystallization.
  • Such methods are disclosed generally in Chiral Separation Techniques: A Practical Approach (2nd Ed.), G. Subramanian (ed.), Wiley-VCH, 2000; T.E. Beesley and R.P.W. Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by
  • halo generally denotes fluorine, chlorine, bromine and iodine.
  • d-n-alkyl wherein n is an integer from 2 to n, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms.
  • C -3 -alkyl embraces the radicals H 3 C-, H 3 C-CH 2 -, H 3 C-CH 2 -CH 2 - and H 3 C-CH(CH 3 )-.
  • carbbocyclyl or “carbocycle” as used herein, either alone or in combination with another radical means a mono-, bi- or tricyclic ring structure consisting of 3 to 14 carbon atoms.
  • Carbocyclyl or “carbocycle” refers to fully saturated and aromatic ring systems and partially saturated ring systems.
  • Carbocyclyl or “carbocycle” encompasses fused, bridged and spirocyclic systems.
  • C 3 - n -cycloalkyl wherein n is an integer 4 to n, either alone or in combination with another radical, denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms.
  • C 3 - 7 -cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • aryl denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to at least one other 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated.
  • Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.
  • heterocyclyl or “heterocycle” is intended to include all the possible isomeric forms and all spiro, bridged and fused systems.
  • heterocyclyl or “heterocyclyl” includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
  • heteroaryl is intended to include all the possible isomeric forms and all spiro, bridged and fused systems.
  • heteroaryl includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • such salts include acetates, ascorbates, benzenesulfonates, benzoates, besylates, bicarbonates, bitartrates, bromides/hydrobromides, Ca-edetates/edetates, camsylates, carbonates, chlorides/hydrochlorides, citrates, edisylates, ethane disulfonates, estolates esylates, fumarates, gluceptates, gluconates, glutamates, glycolates, glycollylarsnilates, hexylresorcinates, hydrabamines, hydroxymaleates,
  • phosphates/diphosphates polygalacturonates, propionates, salicylates, stearates subacetates, succinates, sulfamides, sulfates, tannates, tartrates, teoclates, toluenesulfonates, triethiodides, ammonium, benzathines, chloroprocaines, cholines, diethanolamines, ethylenediamines, meglumines and procaines.
  • Further pharmaceutically acceptable salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like, (also see Pharmaceutical salts, Birge, S.M. et al., J. Pharm. Sci., (1977), 66, 1 -19).
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
  • Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
  • treatment means the administration of a compound or composition according to the present invention to alleviate or eliminate symptoms of CMV disease and/or to reduce viral load in a patient.
  • prevention means the administration of a compound or composition according to the present invention post-exposure of the individual to the virus but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood, to prevent the appearance of symptoms of the disease.
  • terapéuticaally effective amount means an amount of a compound according to the invention, which when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or patient that is sought by a researcher or clinician.
  • the amount of a compound according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of the treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the invention, and the age, body weight, general health, sex and diet of the patient.
  • a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the state of the art, and this disclosure.
  • R 1 Any and each of the definitions below may be combined with each other.
  • R 1 -A R 1 is O or S.
  • R 1 -B R 1 is O.
  • R 1 -C R 1 is S.
  • R R -A R is CH
  • R 1A -B R 1A is N
  • R 1A -C R 1A is CH.
  • Ring Z-A Ring Z is selected from the group consisting of phenyl, pyridine, pyridinone, benzimidazole and benzothiazole wherein each said phenyl, pyridine, pyridinone, benzimidazole and benzothiazole are optionally mono-, di- or tri- substituted with Z 1 ;
  • Z 1 is each independently selected from the group consisting of (d- 6 )alkyL -(Ci_ 6 )alkyl- (C 3 - 7 )cycloalkyL -(Ci- 6 )alkyl-heteroaryl, - (Ci- 6 )alkyl-heterocyclyl and -0-(Ci- 6 )alkyl.
  • Ring Z-B Ring Z is selected from the group consisting of phenyl, pyridine, pyridinone, benzimidazole and benzothiazole.
  • Ring Z-C Ring Z is selected from the group consisting of phenyl, pyridine and pyridinone.
  • Ring Z-D Ring Z is selected from the group consisting of benzimidazole and benzothiazole.
  • R 2A is H or (C 1-6 )alkyl
  • R 3 is absent, (C 3 - 7 )cycloalkyl or (Ci_ 6 )alkyl optionally mono-, di- or tri-substituted with R 3A ;
  • R 2A is H or (d- 6 )alkyl
  • R 3 is absent or (Ci_ 6 )alkyl optionally mono-, di- or tri-substituted with R 3A ;
  • R 3A is each independently selected from the group consisting of OH, -0-(C -6 )alkyl, -O- aryl and -0-(Ci- 6 )alkyl-aryl.
  • R 2 is
  • R 3 is absent or (Ci_ 6 )alkyl optionally mono-, di- or tri-substituted with R 3A ;
  • R 3A is each independently selected from the group consisting of OH, -0-(C -6 )alkyl, -O- aryl and -0-(Ci- 6 )alkyl-aryl.
  • R 4 -A is halo, (d- 6 )haloalkyl, -CN, OH, -0-(d- 6 )alkyl or (Ci -6 )alkyl,
  • R 4 -B R 4 is halo, (d- 6 )haloalkyl, -CN or (Ci -6 )alkyl.
  • R 4 -C R 4 is halo or (C 1-6 )haloalkyl.
  • Examples of most preferred compounds according to this invention are each single compound in Tables 1 .
  • Suitable preparations for administering the compounds of the invention will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders.
  • the content of the pharmaceutically active compound(s) should be in the range from 0.05 to 90 wt.- %, preferably 0.1 to 50 wt.-% of the composition as a whole.
  • Suitable tablets may be obtained, for example, by mixing one or more compounds according to the invention with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
  • excipients for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
  • the tablets may also consist of several layers.
  • Suitable injectables may be obtained, for example, by mixing one or more compounds according to the invention with known excipients, for example inert diluents, carriers, co-solvent, adjuvants, surfactants and/or cyclodextrin complex.
  • the injectable formulation may be an emulsion or suspension.
  • Combination therapy is contemplated wherein a compound of the invention, or a
  • a pharmaceutically acceptable salt thereof is co-administered with at least one additional agent selected from: a CMV entry inhibitor, a CMV early transcription event inhibitor, a CMV helicase- primase inhibitor, a CMV DNA polymerase inhibitor, an inhibitor of UL97 kinase, a CMV protease inhibitor, a CMV terminase inhibitor, a CMV maturation inhibitor, an inhibitor of another target in the CMV life cycle, a CMV vaccine and a CMV biological agent.
  • additional agent selected from: a CMV entry inhibitor, a CMV early transcription event inhibitor, a CMV helicase- primase inhibitor, a CMV DNA polymerase inhibitor, an inhibitor of UL97 kinase, a CMV protease inhibitor, a CMV terminase inhibitor, a CMV maturation inhibitor, an inhibitor of another target in the CMV life cycle, a CMV vaccine and a CMV biological agent.
  • additional agents may be combined with the compounds of this invention to create a single pharmaceutical dosage form.
  • these additional agents may be separately administered to the patient as part of a multiple dosage form, for example, using a kit.
  • Such additional agents may be administered to the patient prior to, concurrently with, or following the administration of a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • the dose range of the compounds of the invention applicable per day is usually from 0.01 to 100 mg/kg of body weight, preferably from 0.1 to 50 mg/kg of body weight.
  • Each dosage unit may conveniently contain from 5% to 95% active compound (w/w).
  • Preferably such preparations contain from 20% to 80% active compound.
  • the actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.
  • composition of this invention comprises a combination of a compound of the invention and one or more additional therapeutic or prophylactic agent
  • both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
  • Antiviral agents contemplated for use in such combination therapy include agents (compounds or biologicals) that are effective to inhibit the production and/or replication of a virus in a human being, including but not limited to agents that interfere with either host or viral mechanisms necessary for the production and/or replication of a virus in a human being.
  • Such agents can be selected from: a CMV entry inhibitor; a CMV early transcription event inhibitor; a CMV helicase- primase inhibitor; a CMV DNA polymerase inhibitor such as Ganciclovir (Cytovene), Valganciclovir (Valcyte; Cymeval), Cidofovir (Vistide), Foscarnet (Foscavir), CMX001 , cyclopropavir (MBX-400) and Valaciclovir (Valtrex; Zelitrex); an inhibitor of UL97 kinase such as Maribavir; a CMV protease inhibitor; a CMV terminase inhibitor such as AIC246 (Letermovir); a CMV maturation inhibitor; other inhibitors such as Artesunate; a CMV vaccine such as TransVax and a CMV biological agent such as Cytogam (Cytotect), TCN-202 and CMV IgG.
  • Ganciclovir Cytovene
  • Valganciclovir Val
  • Compounds and intermediates can be purified by a Teledyne ISCO Combiflash R f System at 254 nm using commercial normal phase silica 4-120 g Redisep R f or Silicycle columns at a flow rate of 18-85 ml. /min depending on column size.
  • Mass spectral analyses may be recorded using flow injection analysis mass spectrometry or Waters Acquity Ultraperformance LC System consisting of a sample organizer, PDA detector, column manager, sample manager, binary solvent manager and SQ detector.
  • Reactions performed in microwave conditions are conducted in a Biotage Initiator 2.0 microwave synthesizer equipped with a Robot Sixty for vial manipulations.
  • the temperature range is from 40-250 °C.
  • the pressure range is from 0-20 bar and the power range is from 0- 400 Watts at 2.45 GHz.
  • the vial size varies from 0.5 ml. to 20 ml_.
  • the solvent absorption level is high by default. Specific reaction times and temperatures are given in the experimental section when applicable.
  • Preparative RP-HPLC is performed under standard conditions using one of the following specific measuring conditions: A) Waters SunFire Prep OBD C18 column (5 ⁇ , 19x50 mm) eluting firstly with a hold period of 1 min in initial gradient condition then eluting with a linear MeOH gradient containing 10 mM Ammonium Formate (pH 3.8) over 10 min at 30 mL/min. Fractions containing the desired product are pooled, concentrated and lyophilized.
  • HPLC high performance liquid chromatography
  • HSS high strength silica
  • 'Pr or i-Pr 1 - methylethyl (/so-propyl);
  • iPrOH isopropanol
  • Me methyl
  • MeCN acetonitrile
  • MeOH methanol
  • MS mass spectrometry
  • [M+H] + protonated molecular ion
  • MTBE or t-MBE tert-butylmethyl ether
  • OBD optimum bed density
  • PDA photodiode array
  • Ph phenyl
  • Pr propyl
  • RP reverse phase
  • RT room temperature (18 to 22 5 C)
  • TEA room temperature
  • a suspension of A1 a (10.0 g, 77.4 mmol, Combi Blocks) in DCM (100 mL) is treated with oxalyl chloride (66.0 mL, 619.5 mmol). Then, DMF (599.6 ⁇ , 7.7 mmol) is added dropwise. The reaction mixture is stirred overnight at RT, and then concentrated under reduced pressure, azeotroped with toluene (150 mL) and dried under high vacuum for 1 h to afford A1 b which is used as is in subsequent reactions.
  • Step 1
  • A2b 600 mg, 2.5 mmol
  • THF 2 mL
  • NaOH 10 M, 1 .1 mL, 10 mmol
  • the reaction is stirred for 3 h.
  • the mixture is concentrated and then is extracted with Et 2 0.
  • the aqueous phase is acidified to pH 2 with concentrated HCI and extracted with EtOAc.
  • the organic layer is washed with brine, dried over Na 2 S0 4 , filtered, and concentrated to provide A2c.
  • Step 1
  • a solution of A2a (2.0 g, 9.2 mmol) in DMSO (12 mL) is cooled to 0 5 C and treated with solid NaH (60% dispersion in mineral oil, 1 .1 g,44 mmol).
  • the reaction is stirred for 15 min and then 1 ,4-dibromobutane (1 .3 mL, 12 mmol) is added.
  • the reaction is warmed to RT and stirred overnight.
  • the reaction is diluted with water, extracted with EtOAc (2x), dried over Na 2 S0 4 and the solvent is removed on the rotovap.
  • the crude mixture is purified by Combiflash to give A3a.
  • Compound A3b is prepared from A3a by analogy to the preparation of compound A2c,
  • Step 1
  • Step 1
  • Step 1
  • a suspension of A1 b (870 mg, 5.7 mmol) and B2a (Maybridge, 780 mg, 4.4 mmol) in DCM (40 mL) is treated with TEA (1 .2 mL, 8.7 mmol). After 20 min, the reaction is concentrated to afford B2b, which is used as is in the next step.
  • Step 1
  • Compound B3b is prepared from B3a (Combiblocks) by analogy to compound B2b, following step 1 from Example B2.
  • Step 1
  • Compound 1131 is prepared from B4d by analogy to the preparation of compound 1122 from compound B2d following steps 2 and 3 from Example B2.
  • Solid Boc 2 0 (28 g, 130 mmol) is added to a solution of B5a1 (Aconpharm, 4.0 g, 36 mmol, Tyger) in MeCN (250 ml_).
  • Solid DMAP 250 mg, 2.0 mmol is added in 50 mg portions at 20 min intervals. The reaction is stirred overnight and then concentrated, diluted with 1 :1 t- BME/EtOAc and washed with 10% citric acid, saturated NaHC0 3 and brine. The organic layer is dried over Na 2 S0 4 and evaporated to dryness. MeOH (80 ml.) and saturated NaHC0 3 (40 ml.) are added and the mixture is stirred 3 d.
  • Step 2 Solid NaH (60% dispersion in mineral oil, 280 mg, 1 .1 mmol) is added to a suspension of B5a (2.0 g, 6.4 mmol) in THF (30 mL) at 0 5 C. Ethyl bromoacetate (0.86 mL, 7.7 mmol) is added to the reaction, which is stirred for 1 h , allowed to warm to RT, and then stirred for an additional 4 h. The mixture is diluted with EtOAc and is washed with water, saturated NaHC0 3 and brine. The organic layer is dried over Na 2 S0 4 , concentrated and the product purified by Combiflash to give B5b.
  • Step 1
  • the aryl malonate intermediate is then taken up in 2:1 DCM/TFA (30 mL/15 mL) and this solution is stirred for 2 h. The solution is evaporated to dryness. The residue taken up in t-BME and washed (2x) with 10% NaHC0 3 and brine. The organic layer is dried over Na 2 S0 4 and evaporated and the product purified by Combiflash to give B6c.
  • a solution of A1 b (300 mg, 2.0 mmol) in DCM (10 mL) is treated with amine B6d (500 mg, 2.3 mmol) followed by DIPEA (1 .0 mL, 5.7 mmol) and the reaction is stirred overnight.
  • the reaction is diluted with t-BME and EtOAc and washed with 10% citric acid, saturated NaHC0 3 and brine. The mixture is filtered and the titrate evaporated to dryness.
  • the product is purified by
  • Compound 1143 is prepared from compounds B6f and B2d by analogy to the preparation of compound 1122 from compound B2c in Example B2.
  • Compound 1158 is prepared from A4a and B7c by analogy to compound 1001 , following step 3 from Example B1 .
  • Step 1
  • Step 1
  • Compound 1037 is prepared from B9e (J.W. Pharma) and B9d by analogy to compound 1098, following step 3 from Example B8.
  • Step 1
  • the amine B10a (Aldrich) (1 .5 g, 9.6 mmol) is weighed in a round bottom flask and dissolved in DCM (25 ml_). Compound A1 b (1 .5 g, 10 mmol) is added followed by DIPEA (2.5 ml_, 14.4 mmol). The reaction is stirred at RT for 1 h and then partitioned between DCM and saturated NaHC0 3 . The organic layer is washed with water and brine, dried over MgS0 4 , filtered and concentrated. The residue is purified by Combiflash to give B10b.
  • Compound 1121 is prepared from compound B10c by analogy to the preparation of compound 1037 from compound B9b following step 2, 3 and 4 of Example B9.
  • Exam le B11 Preparation of Compound 1137
  • Step 1
  • Compound 1137 is prepared from B11a (Oakwood) by analogy to the preparation of compound B9f from compound B10a following step 1 , 2 and 3 of Example B10.
  • This assay format is a CPE (Cytopathic effect)-based assay that determines the ability of compounds to protect cells against infection with a dye reduction assay (MTS of CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay from Promega).
  • MTS dye reduction assay
  • the conversion of MTS into aqueous, soluble formazan is performed by dehydrogenase enzymes found in metabolically active cells.
  • the quantity of formazan product determined by absorbance at 490nm is directly proportional to the number of living cells in culture.
  • 10 ⁇ _ of the freshly prepared 4% DMSO serial dilution plate is added to the assay plate containing 40 ⁇ _ of MRC-5 cells plated the day before (10000 cells per well).
  • Twenty ⁇ _ of diluted virus is added to columns 2-12 and 14-24 and only D-MEM 5% FBS medium to uninfected control (columns 1 and 13) for a final DMSO concentration of 0.6%.
  • the virus dilution is based on the amount of virus required to obtain a Signal-to-Background of
  • the assay plates are incubated at 37 ⁇ C with 5% C0 2 for 9 days in order to obtain 100% CPE in infected control without compound (columns 12 and 24).
  • Ten ⁇ _ of freshly mixed room temperature MTS/PMS (1 :20 v/v) is added and the plates are incubated at 37 ⁇ C with 5% C0 2 for 4-5 h (until signal saturation at 2.3 in the 100% CPE control).
  • the plates are sealed with TopSeal for biosafety and read on the Envision plate reader (Perkin-Elmer) or equivalent at OD 492 nm.
  • This assay format is a luciferase reporter-based assay that determines the ability of compounds to inhibit the infection by detecting a luciferase signal decrease following the addition of BIGIo substrate (preparation indicated below) directly in the culture media.
  • Mono-oxygenation of luciferin is catalyzed by luciferase in the presence of Mg 2+ , ATP and molecular oxygen.
  • the generation of oxyluciferin is a luminescent reaction that can be detected with the proper platereader.
  • Human Cytomegalovirus AD169-Bac is obtained from Dr. Thomas Shenk at Princeton University (reference paper Yu et al. 2002 - J. Virol.
  • NaTPP Na Triphosphate 0.54 mM
  • Serial dilutions of the DMSO stock compound solution are performed using DMSO in columns 2-1 1 and 14-23. DMSO alone is present in columns 1 , 12, 13 and 24. Four ⁇ _ of the DMSO serial dilutions is obtained and diluted using 96 ⁇ _ of D-MEM 5% FBS culture medium to obtain 4% DMSO (7X).
  • ⁇ _ of the freshly prepared 4% DMSO serial dilution plate is added to the assay plate containing 25 ⁇ _ of MRC-5 cells plated the day before (10000 cells per well).
  • Seventeen ⁇ _ of diluted virus is added to columns 2-12 and 14-24 and only D-MEM 5% FBS medium to uninfected control (columns 1 and 13) for a final DMSO concentration of 0.6%.
  • the assay plates are incubated at 37 ⁇ € with 5% C0 2 for 3 days.
  • EXAMPLE C HCMV AD169 qPCR 96-well Assay
  • the hCMV quantitative PCR (qPCR) assay evaluates the ability of a compound to inhibit, directly or indirectly, the replication of hCMV viral DNA during the first 72h following the infection. Compounds that inhibit either entry or the hCMV polymerase are active in this assay. Compounds are tested in the qPCR assay in 96-well plates, using a 9-point dose-response with 8 compounds for each 96-well plate.
  • the assay was adapted from the method described by Schnepf et al., Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR, Antiviral Research 81 (2009) 64-67.
  • qHCMV7 US17 Forward primer, 5' GAA GGT GCA GGT GCC CTG 3' (SEQ ID NO: 1 ), synthesis by IDT.
  • qHCMV8 US17 Reverse primer, 5' GTG TCG ACG AAC GAC GTA CG 3' (SEQ ID NO: 2), synthesis by IDT.
  • RP8LL mitochodrial Forward primer, 5' ACC CAC TCC CTC TTA GCC AAT ATT 3' (SEQ ID NO: 4), synthesis by IDT
  • RP9LL mitochodrial Reverse primer, 5' GTA GGG CTA GGC CCA CCG 3' (SEQ ID NO: 5), synthesis by IDT
  • RP1 1 LL mitochodrial probe with JOE probe with Iowa Black FQ quencher, 5' JOE-CTA GTC TTT GCC GCC TGC GAA GCA- IABkFQ-3' (SEQ ID NO: 6), synthesis by IDT
  • the cell lysate is carefully pipetted up and down to mix well and diluted 1 :40 in H 2 0 to give a final dilution of 1 :80 relative to the 100 ⁇ _ of lysis buffer that Is added to the cells. 5 ⁇ _ of diluted lysate is used for the qPCR reaction. An incubation of 5 minutes at 95 ⁇ in a PCR machine is required to inactivate the Proteinase K.
  • the cell lysates can be stored at -20 ⁇ or used to perform qPCR immediately.
  • a 81 bp fragment of US17 gene from AD169 is amplified by PCR using primers qHCMV7 and qHCMV8.
  • the PCR product is cloned into pCR4 TOPO vector (Invitrogen) and a clone harboring the insert is selected.
  • a mitochondrial DNA is also added to normalize the HCMV copy number.
  • Serial dilutions of the US17 plasmid and mitochondrial DNA are performed in heat-inactivated lysis buffer at the same dilution as the cell lysates (1 :80). Usually, a standard curve ranging from 10E6 to 10E2 copies (per well) is suitable.
  • a typical qPCR reaction consists of the following:
  • a qPCR cycle consists of an initial denaturation of DNA and activation of the Taq enzyme at 95 °C for 10 min followed by 45 cycles of 15 seconds at 95 °C and 1 min at 60 °C. Fluorescence is measured at each cycle, following the elongation step at 60 °C.
  • the reaction, data acquisition and analysis are performed using AppliedBiosystems 7500 Real time PCR system or other suitable real-time PCR system.
  • Retention times (t R ) for each compound are measured using the standard analytical HPLC or UPLC conditions described in the Examples.
  • retention time values are sensitive to the specific measurement conditions. Therefore, even if identical conditions of solvent, flow rate, linear gradient, and the like are used, the retention time values may vary when measured, for example, on different HPLC or UPLC instruments. Even when measured on the same instrument, the values may vary when measured, for example, using different individual HPLC or UPLC columns, or, when measured on the same instrument and the same individual column, the values may vary, for example, between individual measurements taken on different occasions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2013/067674 2012-11-03 2013-10-31 Inhibitors of cytomegalovirus WO2014070979A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP13792795.0A EP2914592B1 (en) 2012-11-03 2013-10-31 Inhibitors of cytomegalovirus
US14/440,087 US9334249B2 (en) 2012-11-03 2013-10-31 Inhibitors of cytomegalovirus
JP2015540765A JP6372666B2 (ja) 2012-11-03 2013-10-31 サイトメガロウイルスの阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722152P 2012-11-03 2012-11-03
US61/722,152 2012-11-03

Publications (1)

Publication Number Publication Date
WO2014070979A1 true WO2014070979A1 (en) 2014-05-08

Family

ID=49620281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/067674 WO2014070979A1 (en) 2012-11-03 2013-10-31 Inhibitors of cytomegalovirus

Country Status (4)

Country Link
US (1) US9334249B2 (enrdf_load_stackoverflow)
EP (1) EP2914592B1 (enrdf_load_stackoverflow)
JP (1) JP6372666B2 (enrdf_load_stackoverflow)
WO (1) WO2014070979A1 (enrdf_load_stackoverflow)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640517B2 (en) 2014-01-13 2020-05-05 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US10758518B2 (en) 2017-10-31 2020-09-01 Curis, Inc. Compounds and compositions for treating hematological disorders
CN112812111A (zh) * 2020-03-03 2021-05-18 中国药科大学 苯并噻唑类化合物及医药用途
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
US11419875B2 (en) 2017-03-31 2022-08-23 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
EP4163272A4 (en) * 2020-06-08 2024-07-24 Shenyang Pharmaceutical University BENZOTHIAZOLE DERIVATIVE AND ITS USE
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
US12410193B2 (en) 2014-01-13 2025-09-09 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022026863A2 (en) * 2020-07-31 2022-02-03 Emory University Cystic fibrosis transmembrane conductance regulator (cftr) modulators, pharmaceutical compositions, and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034261A2 (en) * 1998-12-09 2000-06-15 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
WO2000034258A2 (en) * 1998-12-09 2000-06-15 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
WO2000034238A1 (en) * 1998-12-09 2000-06-15 American Home Products Corporation Thiourea inhibitors of herpes viruses
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
WO2002085869A1 (de) * 2001-04-19 2002-10-31 Bayer Aktiengesellschaft Arylsulfonamide als antivirale mittel
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2010043377A1 (en) * 2008-10-14 2010-04-22 Almirall, S.A. New 2-amidothiadiazole derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536533A (ja) 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
JP5225857B2 (ja) 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
EP2069287A1 (en) * 2006-09-11 2009-06-17 Syngeta Participations AG Insecticidal compounds
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034261A2 (en) * 1998-12-09 2000-06-15 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
WO2000034258A2 (en) * 1998-12-09 2000-06-15 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
WO2000034238A1 (en) * 1998-12-09 2000-06-15 American Home Products Corporation Thiourea inhibitors of herpes viruses
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
WO2002085869A1 (de) * 2001-04-19 2002-10-31 Bayer Aktiengesellschaft Arylsulfonamide als antivirale mittel
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2010043377A1 (en) * 2008-10-14 2010-04-22 Almirall, S.A. New 2-amidothiadiazole derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Chiral Separation Techniques: A Practical Approach", 2000, WILEY-VCH
BIRGE, S.M. ET AL.: "Pharmaceutical salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
SATINDER AHUJA: "Chiral Separations by Chromatography", 2000, AM. CHEM. SOC.
SCHNEPF ET AL.: "Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR", ANTIVIRAL RESEARCH, vol. 81, 2009, pages 64 - 67, XP025761848, DOI: doi:10.1016/j.antiviral.2008.09.009
T.E. BEESLEY; R.P.W. SCOTT: "Chiral Chromatography", 1999, JOHN WILEY & SONS
YU ET AL., J. VIROL., vol. 76, no. 5, 2002, pages 2316 - 2328

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640517B2 (en) 2014-01-13 2020-05-05 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US12410193B2 (en) 2014-01-13 2025-09-09 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US10995100B2 (en) 2014-01-13 2021-05-04 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US11981685B2 (en) 2014-01-13 2024-05-14 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US11691987B2 (en) 2014-01-13 2023-07-04 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US11419875B2 (en) 2017-03-31 2022-08-23 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
US10758518B2 (en) 2017-10-31 2020-09-01 Curis, Inc. Compounds and compositions for treating hematological disorders
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
US12338220B2 (en) 2019-09-26 2025-06-24 Gilead Sciences, Inc. Antiviral pyrazolopiridinone compounds
WO2021175234A1 (zh) * 2020-03-03 2021-09-10 中国药科大学 苯并噻唑类化合物及医药用途
CN112812111A (zh) * 2020-03-03 2021-05-18 中国药科大学 苯并噻唑类化合物及医药用途
EP4163272A4 (en) * 2020-06-08 2024-07-24 Shenyang Pharmaceutical University BENZOTHIAZOLE DERIVATIVE AND ITS USE
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer

Also Published As

Publication number Publication date
US20150284348A1 (en) 2015-10-08
EP2914592A1 (en) 2015-09-09
EP2914592B1 (en) 2017-10-11
US9334249B2 (en) 2016-05-10
JP6372666B2 (ja) 2018-08-15
JP2016503403A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
EP2914592B1 (en) Inhibitors of cytomegalovirus
EP2914591B1 (en) Inhibitors of cytomegalovirus
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
CA2880251C (en) Novel heteroaryl and heterocycle compounds, composition and methods thereof
EP2855472B1 (en) Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
AU2018285131B2 (en) Heteroaromatic compounds as Vanin inhibitors
EP2855479B1 (en) 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
RU2621734C1 (ru) Гетеробициклические производные в качестве ингибиторов hcv
CA2805440A1 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP3063149A1 (en) Quinazoline based respiratory syncytial virus inhibitors
JP5580814B2 (ja) ３環式インドール誘導体およびその使用方法
US9505775B2 (en) Inhibitors of cytomegalovirus
MX2014008042A (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
WO2015065336A1 (en) Respiratory syncytial virus inhibitors
EP4282862A1 (en) Flavivirus inhibitors
US20230077499A1 (en) Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses
WO2016179059A1 (en) Heteroaryl-pyrimidinone compounds as pde2 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13792795

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2013792795

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013792795

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015540765

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14440087

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE